<DOC>
	<DOCNO>NCT00848926</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , pivotal clinical trial evaluate efficacy safety brentuximab vedotin ( SGN-35 ) single agent patient relapse refractory Hodgkin lymphoma .</brief_summary>
	<brief_title>A Pivotal Open-Label Trial Brentuximab Vedotin Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients relapse refractory Hodgkin lymphoma previously receive autologous stem cell transplant . Histologically confirm CD30positive disease ; tissue recent post diagnostic biopsy relapsed/refractory disease must available confirmation CD30 expression via slide tumor block . Fluorodeoxyglucoseavid disease positron emission tomography measurable disease least 1.5 cm document spiral compute tomography . At US sit patient great equal 12 year age may enrol . At nonUS site patient must great equal 18 year age . Previous treatment brentuximab vedotin . Previously receive allogeneic transplant . Congestive heart failure , Class III IV , New York Heart Association criterion . History another primary malignancy remission least 3 year . Known cerebral/meningeal disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>